{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T18:11:17Z","timestamp":1791655877380,"version":"4.3.4"},"reference-count":163,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T00:00:00Z","timestamp":1712707200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019304","name":"Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019304","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019305","name":"Manipal Academy of Higher Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019305","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.lfs.2024.122614","type":"journal-article","created":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T02:07:26Z","timestamp":1712714846000},"page":"122614","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Precision nanomedicine to treat non-small cell lung cancer"],"prefix":"10.1016","volume":"346","author":[{"given":"Akanksha","family":"Dessai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usha Yogendra","family":"Nayak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yogendra","family":"Nayak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lfs.2024.122614_bb0005","series-title":"Lung Cancer","author":"Siddiqui","year":"2023"},{"key":"10.1016\/j.lfs.2024.122614_bb0010","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.lfs.2024.122614_bb0015","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.lfs.2024.122614_bb0020","doi-asserted-by":"crossref","first-page":"4727","DOI":"10.1038\/s41598-023-31991-0","article-title":"Occupation as a risk factor of small cell lung cancer","volume":"13","author":"Garc\u00eda","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lfs.2024.122614_bb0025","doi-asserted-by":"crossref","first-page":"725","DOI":"10.3390\/ph14080725","article-title":"Pulmonary delivery of anticancer drugs via lipid-based nanocarriers for the treatment of lung cancer: an update","volume":"14","author":"Abdulbaqi","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.lfs.2024.122614_bb0030","series-title":"57- Lung Metastases","author":"Hayman","year":"2020"},{"key":"10.1016\/j.lfs.2024.122614_bb0035","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1080\/17476348.2019.1645010","article-title":"The impact of smoking and the influence of other factors on lung cancer","volume":"13","author":"Schuller","year":"2019","journal-title":"Expert Rev. Respir. Med."},{"key":"10.1016\/j.lfs.2024.122614_bb0040","doi-asserted-by":"crossref","first-page":"646","DOI":"10.21037\/tlcr-19-403","article-title":"The contribution of hereditary cancer-related germline mutations to lung cancer susceptibility","volume":"9","author":"Liu","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.lfs.2024.122614_bb0045","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1080\/10937404.2019.1643539","article-title":"Overview of biological mechanisms of human carcinogens","volume":"22","author":"Birkett","year":"2019","journal-title":"J. Toxic. Environ. Health, Part B"},{"key":"10.1016\/j.lfs.2024.122614_bb0050","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/mas.21570","article-title":"DNA adducts: formation, biological effects, and new biospecimens for mass spectrometric measurements in humans","volume":"39","author":"Yun","year":"2020","journal-title":"Mass Spectrom. Rev."},{"key":"10.1016\/j.lfs.2024.122614_bb0055","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.3390\/cancers15051595","article-title":"Assessment of barriers and challenges to screening, diagnosis, and biomarker testing in early-stage lung cancer","volume":"15","author":"Zarinshenas","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.lfs.2024.122614_bb0060","first-page":"375","article-title":"Lung cancer in non-smokers","volume":"117","author":"Dubin","year":"2020","journal-title":"Mo. Med."},{"key":"10.1016\/j.lfs.2024.122614_bb0065","series-title":"Non-small Cell Lung Cancer","author":"Clark","year":"2023"},{"key":"10.1016\/j.lfs.2024.122614_bb0070","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.3390\/cells9102308","article-title":"Cancer metabolism: phenotype, signaling and therapeutic targets","volume":"9","author":"Park","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.lfs.2024.122614_bb0075","doi-asserted-by":"crossref","first-page":"981","DOI":"10.7150\/ijms.34739","article-title":"Molecular hetero- geneity in lung cancer: from mechanisms of origin to clinical implications","volume":"16","author":"Zito Marino","year":"2019","journal-title":"Int. J. Med. Sci."},{"key":"10.1016\/j.lfs.2024.122614_bb0080","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.3390\/pharmaceutics13122120","article-title":"Signaling pathway inhibitors, miRNA, and Nanocarrier-based pharmacotherapeutics for the treatment of lung cancer: a review","volume":"13","author":"Md","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.lfs.2024.122614_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114452","article-title":"Investigating regulated signaling pathways in therapeutic targeting of non-small cell lung carcinoma","volume":"161","author":"Alam","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.lfs.2024.122614_bb0090","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/j.eng.2020.04.017","article-title":"Nanotechnology and nanomedicine: a promising avenue for lung cancer diagnosis and therapy","volume":"7","author":"Yin","year":"2021","journal-title":"Engineering"},{"key":"10.1016\/j.lfs.2024.122614_bb0095","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.3390\/ijms23031853","article-title":"Nanomedicine strategies for management of drug resistance in lung cancer","volume":"23","author":"Haider","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2024.122614_bb0100","doi-asserted-by":"crossref","DOI":"10.1177\/10732748221077351","article-title":"Precision medicine in lung cancer theranostics: paving the way from traditional technology to advance era","volume":"29","author":"Guan","year":"2022","journal-title":"Cancer Control"},{"key":"10.1016\/j.lfs.2024.122614_bb0105","doi-asserted-by":"crossref","first-page":"5700","DOI":"10.3390\/cancers14225700","article-title":"The multidisciplinary approach in stage III non-small cell lung cancer over ten years: from radiation therapy optimisation to innovative systemic treatments","volume":"14","author":"Ferro","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.lfs.2024.122614_bb0110","doi-asserted-by":"crossref","first-page":"S898","DOI":"10.21037\/jtd.2018.01.172","article-title":"Surgical treatment for early stage non-small cell lung cancer","volume":"10","author":"Raman","year":"2018","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.lfs.2024.122614_bb0115","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/9181549","article-title":"The synergistic anticancer effect of dual drug- (cisplatin\/epigallocatechin gallate) loaded gelatin nanoparticles for lung cancer treatment","volume":"2020","author":"Chen","year":"2020","journal-title":"J. Nanomater."},{"key":"10.1016\/j.lfs.2024.122614_bb0120","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3727\/096504019X15755437099308","article-title":"Vinorelbine in non-small cell lung cancer: real-world data from a single-institution experience","volume":"28","author":"Nobili","year":"2020","journal-title":"Oncol. Res."},{"key":"10.1016\/j.lfs.2024.122614_bb0125","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.958505","article-title":"State-of-the-art combination treatment strategies for advanced stage non\u2013small cell lung cancer","volume":"12","author":"Yao","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.lfs.2024.122614_bb0130","article-title":"Paclitaxel for treatment of advanced small cell lung cancer (SCLC): a retrospective study of 185 patients","volume":"12","author":"Eiff","year":"2020","journal-title":"Journal of Thoracic Disease"},{"key":"10.1016\/j.lfs.2024.122614_bb0135","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1177\/1758834016644155","article-title":"Pemetrexed for advanced stage nonsquamous non-small cell lung cancer: latest evidence about its extended use and outcomes","volume":"8","author":"Tomasini","year":"2016","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.lfs.2024.122614_bb0140","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.3390\/vaccines10111801","article-title":"The anti-tumor and immunomodulatory effects of PLGA-based docetaxel nanoparticles in lung cancer: the potential involvement of necroptotic cell death through reactive oxygen species and calcium build-up","volume":"10","author":"Gupta","year":"2022","journal-title":"Vaccines"},{"key":"10.1016\/j.lfs.2024.122614_bb0145","doi-asserted-by":"crossref","first-page":"139","DOI":"10.21037\/atm.2018.04.04","article-title":"Novel chemotherapy regimens for advanced lung cancer: have we reached a plateau?","volume":"6","author":"Baxevanos","year":"2018","journal-title":"Annals of Translational Medicine"},{"key":"10.1016\/j.lfs.2024.122614_bb0150","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2024.122614_bb0155","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1093\/annonc\/mdw611","article-title":"Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-lung 7 trial","volume":"28","author":"Paz-Ares","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lfs.2024.122614_bb0160","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1080\/14712598.2018.1508445","article-title":"Necitumumab in the treatment of non-small-cell lung cancer: clinical controversies","volume":"18","author":"di Noia","year":"2018","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.lfs.2024.122614_bb0165","doi-asserted-by":"crossref","DOI":"10.1177\/1753466619831906","article-title":"Alectinib in the treatment of ALK-positive metastatic non-small cell lung cancer: clinical trial evidence and experience with a focus on brain metastases","volume":"13","author":"Tomasini","year":"2019","journal-title":"Ther. Adv. Respir. Dis."},{"key":"10.1016\/j.lfs.2024.122614_bb0170","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1093\/jjco\/hyaa192","article-title":"Brigatinib and lorlatinib: their effect on ALK inhibitors in NSCLC focusing on resistant mutations and central nervous system metastases","volume":"51","author":"Naito","year":"2021","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.lfs.2024.122614_bb0175","doi-asserted-by":"crossref","first-page":"5983","DOI":"10.1158\/1078-0432.CCR-16-0917","article-title":"Crizotinib-resistant ROS1 mutations reveal a predictive kinase inhibitor sensitivity model for ROS1- and ALK-rearranged lung cancers","volume":"22","author":"Facchinetti","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lfs.2024.122614_bb0180","doi-asserted-by":"crossref","first-page":"4295","DOI":"10.2147\/OTT.S145036","article-title":"Improvement of survival for non-small cell lung cancer over time","volume":"10","author":"Xia","year":"2017","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.lfs.2024.122614_bb0185","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/1759-7714.13830","article-title":"Symptom trajectories during chemotherapy in patients with non-small cell lung cancer (NSCLC) and the function of prolonging low dose dexamethasone in promoting enhanced recovery after chemotherapy","volume":"12","author":"Liu","year":"2021","journal-title":"Thoracic Cancer"},{"key":"10.1016\/j.lfs.2024.122614_bb0190","article-title":"Chemotherapy toxicity in advanced non-small cell lung cancer and its impact on survival","volume":"48","author":"Cherif","year":"2016","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.lfs.2024.122614_bb0195","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00391-2017","article-title":"What is precision medicine?","volume":"50","author":"K\u00f6nig","year":"2017","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.lfs.2024.122614_bb0200","first-page":"108","article-title":"Realizing the promise of personalized medicine","volume":"85","author":"Aspinall","year":"2007","journal-title":"Harv. Bus. Rev."},{"key":"10.1016\/j.lfs.2024.122614_bb0205","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/cts.12884","article-title":"Precision medicine, AI, and the future of personalized health care","volume":"14","author":"Johnson","year":"2021","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.lfs.2024.122614_bb0210","first-page":"8","article-title":"Precision and personalized medicine: what their current definition says and silences about the model of health they promote. Implication for the development of personalized health","author":"Delpierre","year":"2023","journal-title":"Front. Sociol."},{"key":"10.1016\/j.lfs.2024.122614_bb0215","doi-asserted-by":"crossref","first-page":"217","DOI":"10.5306\/wjco.v12.i4.217","article-title":"Oncogenic driver mutations in non-small cell lung cancer: past, present and future","volume":"12","author":"Chevallier","year":"2021","journal-title":"World J Clin Oncol"},{"key":"10.1016\/j.lfs.2024.122614_bb0220","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.3390\/cancers13092172","article-title":"Genomic characterization of concurrent alterations in non-small cell lung cancer (NSCLC) harboring actionable mutations","volume":"13","author":"Passaro","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.lfs.2024.122614_bb0225","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3892\/ijo.2022.5436","article-title":"Gefitinib enhances the anti-tumor immune response against EGFR-mutated NSCLC by upregulating B7H5 expression and activating T cells via CD28H","volume":"61","author":"Guo","year":"2022","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.lfs.2024.122614_bb0230","unstructured":"Genprex, Inc. Phase I\/II Clinical Trial Combining TUSC2-nanoparticles and Erlotinib in Stage IV Lung Cancer. clinicaltrials.gov; 2022."},{"key":"10.1016\/j.lfs.2024.122614_bb0235","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cllc.2022.11.004","article-title":"Amivantamab, an epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET) bispecific antibody, designed to enable multiple mechanisms of action and broad clinical applications","volume":"24","author":"Cho","year":"2023","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.lfs.2024.122614_bb0240","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1158\/1078-0432.CCR-22-2072","article-title":"FDA approval summary: mobocertinib for metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations","volume":"29","author":"Duke","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lfs.2024.122614_bb0245","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1111\/1759-7714.14222","article-title":"Efficacy of dacomitinib in patients with EGFR-mutated NSCLC and brain metastases","volume":"12","author":"Zhang","year":"2021","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.lfs.2024.122614_bb0250","article-title":"Ceritinib efficacy and safety in treatment-naive Asian patients with advanced ALK-rearranged NSCLC: an ASCEND-4 subgroup analysis","volume":"2","author":"Tan","year":"2020","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.lfs.2024.122614_bb0255","doi-asserted-by":"crossref","first-page":"4751","DOI":"10.21037\/jtd-22-1606","article-title":"Ensartinib in advanced ALK-positive non-small cell lung cancer: a multicenter, open-label, two-staged, phase 1 trial","volume":"14","author":"Ma","year":"2022","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.lfs.2024.122614_bb0260","article-title":"A phase 2 study of Lorlatinib in patients with ROS1-rearranged lung Cancer with brain-only progression on crizotinib","volume":"3","author":"Schneider","year":"2022","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.lfs.2024.122614_bb0265","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S1470-2045(19)30690-4","article-title":"Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials","volume":"21","author":"Drilon","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lfs.2024.122614_bb0270","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1093\/annonc\/mdz131","article-title":"Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001","volume":"30","author":"Shaw","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lfs.2024.122614_bb0275","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.3390\/ijms24021195","article-title":"Efficacy of dabrafenib and trametinib in a patient with squamous-cell carcinoma, with mutation p.D594G in BRAF and p.R461* in NF1 genes\u2014a case report with literature review","volume":"24","author":"Grenda","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2024.122614_bb0280","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.annonc.2019.10.022","article-title":"Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations","volume":"31","author":"Mazieres","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lfs.2024.122614_bb0285","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.jtho.2021.02.010","article-title":"Crizotinib in patients with MET-amplified NSCLC","volume":"16","author":"Camidge","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lfs.2024.122614_bb0290","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa2002787","article-title":"Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer","volume":"383","author":"Wolf","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2024.122614_bb0295","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1158\/1078-0432.CCR-21-2733","article-title":"Tepotinib efficacy and safety in patients with MET exon 14 skipping NSCLC: outcomes in patient subgroups from the VISION study with relevance for clinical practice","volume":"28","author":"Le","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lfs.2024.122614_bb0300","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.2147\/OTT.S234733","article-title":"Effective treatment with cabozantinib in an advanced non-small-cell lung cancer patient harboring a CD74-ROS1 fusion: a case report","volume":"13","author":"Wang","year":"2020","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.lfs.2024.122614_bb0305","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s11523-022-00935-5","article-title":"Selpercatinib: a review in advanced RET fusion-positive NSCLC","volume":"18","author":"Nie","year":"2023","journal-title":"Target. Oncol."},{"key":"10.1016\/j.lfs.2024.122614_bb0310","doi-asserted-by":"crossref","first-page":"496","DOI":"10.21037\/atm-22-1237","article-title":"Pralsetinib for the treatment of a RET-positive advanced non-small-cell lung cancer patient harboring both ANK-RET and CCDC6-RET fusions with coronary heart disease: a case report","volume":"10","author":"Meng","year":"2022","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.lfs.2024.122614_bb0315","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1093\/annonc\/mdw559","article-title":"Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial","volume":"28","author":"Lee","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lfs.2024.122614_bb0320","doi-asserted-by":"crossref","DOI":"10.1200\/PO.22.00697","article-title":"Response to repotrectinib after development of NTRK resistance mutations on first- and second-generation TRK inhibitors","author":"Chen","year":"2023","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.lfs.2024.122614_bb0325","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1\u20132 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lfs.2024.122614_bb0330","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.2147\/OTT.S177051","article-title":"Antitumor activity of larotrectinib in tumors harboring NTRK gene fusions: a short review on the current evidence","volume":"12","author":"Ricciuti","year":"2019","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.lfs.2024.122614_bb0335","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa2204619","article-title":"Adagrasib in non\u2013small-cell lung cancer harboring a KRASG12C mutation","volume":"387","author":"J\u00e4nne","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2024.122614_bb0340","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1158\/1078-0432.CCR-21-3074","article-title":"FDA approval summary: sotorasib for KRAS G12C-mutated metastatic NSCLC","volume":"28","author":"Nakajima","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lfs.2024.122614_bb0345","first-page":"121","article-title":"Effectiveness and safety of atezolizumab, nivolumab and pembrolizumab in metastatic non-small cell lung cancer","volume":"45","author":"Jos\u00e9","year":"2021","journal-title":"Farm. Hosp."},{"key":"10.1016\/j.lfs.2024.122614_bb0350","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.jtho.2020.12.015","article-title":"Four-year survival with durvalumab after chemoradiotherapy in stage III NSCLC\u2014an update from the PACIFIC trial","volume":"16","author":"Faivre-Finn","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lfs.2024.122614_bb0355","unstructured":"Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial | Nature Medicine n.d. https:\/\/www. nature.com\/articles\/s41591-022-01977-y (accessed November 18, 2023)."},{"key":"10.1016\/j.lfs.2024.122614_bb0360","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1038\/s41591-023-02461-x","article-title":"First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trial","volume":"29","author":"Liu S-YM","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.lfs.2024.122614_bb0365","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.jtho.2023.03.016","article-title":"Poziotinib in treatment-naive NSCLC harboring HER2 exon 20 mutations: ZENITH20-4, a multicenter, multicohort, open-label, phase 2 trial (cohort 4)","volume":"18","author":"Cornelissen","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lfs.2024.122614_bb0370","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/s41586-021-03898-1","article-title":"Structure-based classification predicts drug response in EGFR-mutant NSCLC","volume":"597","author":"Robichaux","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.lfs.2024.122614_bb0375","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s43440-020-00131-0","article-title":"Advances in targeting EGFR allosteric site as anti-NSCLC therapy to overcome the drug resistance","volume":"72","author":"Maity","year":"2020","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.lfs.2024.122614_bb0380","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s13045-022-01391-4","article-title":"Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance","volume":"15","author":"Fu","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.lfs.2024.122614_bb0385","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1158\/1078-0432.CCR-05-1362","article-title":"Molecular context of the EGFR mutations: evidence for the activation of mTOR\/S6K signaling","volume":"12","author":"Conde","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lfs.2024.122614_bb0390","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/nrc.2017.84","article-title":"Understanding and targeting resistance mechanisms in NSCLC","volume":"17","author":"Rotow","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.lfs.2024.122614_bb0395","doi-asserted-by":"crossref","first-page":"S247","DOI":"10.21037\/tlcr.2019.06.01","article-title":"Third-generation epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer","volume":"8","author":"Andrews Wright","year":"2019","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.lfs.2024.122614_bb0400","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.3390\/cells11203200","article-title":"Biomarker-targeted therapies in non-small cell lung cancer: current status and perspectives","volume":"11","author":"Guo","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.lfs.2024.122614_bb0405","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.3390\/ijms22083815","article-title":"Future perspectives in detecting EGFR and ALK gene alterations in liquid biopsies of patients with NSCLC","volume":"22","author":"Ferreira","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2024.122614_bb0410","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/1759-7714.12613","article-title":"ALK-rearrangement in non-small-cell lung cancer (NSCLC)","volume":"9","author":"Du","year":"2018","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.lfs.2024.122614_bb0415","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12943-018-0776-2","article-title":"Role and targeting of anaplastic lymphoma kinase in cancer","volume":"17","author":"Della Corte","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.lfs.2024.122614_bb0420","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1158\/2159-8290.CD-16-1123","article-title":"Targeting ALK: precision medicine takes on drug resistance","volume":"7","author":"Lin","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.lfs.2024.122614_bb0425","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2213-2600(19)30252-8","article-title":"Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial","volume":"8","author":"Yang","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.lfs.2024.122614_bb0430","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12943-018-0810-4","article-title":"The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC)","volume":"17","author":"Golding","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.lfs.2024.122614_bb0435","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.713530","article-title":"The resistance mechanisms and treatment strategies for ALK-rearranged non-small cell lung cancer","volume":"11","author":"Pan","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.lfs.2024.122614_bb0440","doi-asserted-by":"crossref","DOI":"10.21037\/tlcr.2016.06.10","article-title":"Tackling ALK in non-small cell lung cancer: the role of novel inhibitors","volume":"5","author":"Facchinetti","year":"2016","journal-title":"Translational Lung Cancer Research"},{"key":"10.1016\/j.lfs.2024.122614_bb0445","unstructured":"Genetics of Non-Small Cell Lung Cancer: Practice Essentials, Targeting the Genetic Mutations, Genetic Testing 2024."},{"key":"10.1016\/j.lfs.2024.122614_bb0450","doi-asserted-by":"crossref","first-page":"332","DOI":"10.20517\/cdr.2022.105","article-title":"Importance of ROS1 gene fusions in non-small cell lung cancer","volume":"6","author":"Muminovic","year":"2023","journal-title":"Cancer Drug Resistance"},{"key":"10.1016\/j.lfs.2024.122614_bb0455","doi-asserted-by":"crossref","first-page":"641","DOI":"10.3390\/curroncol29020057","article-title":"ROS-1 fusions in non-small-cell lung cancer: evidence to date","volume":"29","author":"Gendarme","year":"2022","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.lfs.2024.122614_bb0460","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1002\/ijc.33447","article-title":"Clinicopathologic, genomic and protein expression characterization of 356 ROS1 fusion driven solid tumors cases","volume":"148","author":"Huang","year":"2021","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.lfs.2024.122614_bb0465","first-page":"4","article-title":"ROS-1 NSCLC therapy resistance mechanism","author":"Garc\u00eda-Pardo","year":"2021","journal-title":"Precision Cancer Medicine"},{"key":"10.1016\/j.lfs.2024.122614_bb0470","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1158\/2159-8290.CD-16-0596","article-title":"Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer","volume":"6","author":"Gainor","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.lfs.2024.122614_bb0475","doi-asserted-by":"crossref","first-page":"11495","DOI":"10.3390\/ijms241411495","article-title":"Therapeutical options in ROS1\u2014rearranged advanced non small cell lung cancer","volume":"24","author":"Stanzione","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2024.122614_bb0480","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.00268","article-title":"Diverse mechanisms of BRAF inhibitor resistance in melanoma identified in clinical and preclinical studies","volume":"9","author":"Luebker","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.lfs.2024.122614_bb0485","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ctrv.2018.04.006","article-title":"BRAF in non-small cell lung cancer (NSCLC): pickaxing another brick in the wall","volume":"66","author":"Leonetti","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.lfs.2024.122614_bb0490","article-title":"BRAF-mutated non-small cell lung cancer: current treatment status and future perspective","volume":"12","author":"Yan","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.lfs.2024.122614_bb0495","doi-asserted-by":"crossref","first-page":"5","DOI":"10.21037\/atm.2016.12.67","article-title":"MET: roles in epithelial-mesenchymal transition and cancer stemness","volume":"5","author":"Jeon","year":"2017","journal-title":"Annals of Translational Medicine"},{"key":"10.1016\/j.lfs.2024.122614_bb0500","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12943-018-0796-y","article-title":"Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities","volume":"17","author":"Zhang","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.lfs.2024.122614_bb0505","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1038\/s41388-020-01577-5","article-title":"The role of MET in chemotherapy resistance","volume":"40","author":"Wood","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.lfs.2024.122614_bb0510","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1080\/14737140.2019.1643239","article-title":"Capmatinib for the treatment of non-small cell lung cancer","volume":"19","author":"Vansteenkiste","year":"2019","journal-title":"Expert. Rev. Anticancer. Ther."},{"key":"10.1016\/j.lfs.2024.122614_bb0515","doi-asserted-by":"crossref","unstructured":"MET Exon 14 Skipping Mutations in Non\u2013Small-Cell Lung Cancer: An Overview of Biology, Clinical Outcomes, and Testing Considerations | JCO Precision Oncology n.d. https:\/\/ascopubs. org\/doi\/https:\/\/doi.org\/10.1200\/PO.20.00516 (accessed March 27, 2024).","DOI":"10.1200\/PO.20.00516"},{"key":"10.1016\/j.lfs.2024.122614_bb0520","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtocrr.2023.100630","article-title":"Targeting MET in NSCLC: an ever-expanding territory","volume":"5","author":"Han","year":"2024","journal-title":"JTO Clinical and Research Reports"},{"key":"10.1016\/j.lfs.2024.122614_bb0525","doi-asserted-by":"crossref","DOI":"10.7573\/dic.2022-1-5","article-title":"Non-small-cell lung cancer: how to manage RET-positive disease","volume":"11","author":"Andrini","year":"2022","journal-title":"Drugs Context"},{"key":"10.1016\/j.lfs.2024.122614_bb0530","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1033484","article-title":"Targeted therapy of RET fusion-positive non-small cell lung cancer","volume":"12","author":"Shen","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.lfs.2024.122614_bb0535","first-page":"583","article-title":"Expert consensus on clinical practice of RET fusion detection in non-small cell lung cancer in China","volume":"50","year":"2021","journal-title":"Zhonghua Bing Li Xue Za Zhi"},{"key":"10.1016\/j.lfs.2024.122614_bb0540","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s40265-022-01720-4","article-title":"Pralsetinib: a review in advanced RET fusion-positive NSCLC","volume":"82","author":"Syed","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.lfs.2024.122614_bb0545","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/j.annonc.2020.09.015","article-title":"Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer","volume":"31","author":"Lin","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lfs.2024.122614_bb0550","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1007\/s00018-006-6010-1","article-title":"Neurotrophin signaling: many exciting surprises!","volume":"63","author":"Ar\u00e9valo","year":"2006","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.lfs.2024.122614_bb0555","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1080\/14737140.2019.1643239","article-title":"Capmatinib for the treatment of non-small cell lung cancer","volume":"19","author":"Vansteenkiste","year":"2019","journal-title":"Expert. Rev. Anticancer. Ther."},{"key":"10.1016\/j.lfs.2024.122614_bb0560","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41571-018-0113-0","article-title":"NTRK fusion-positive cancers and TRK inhibitor therapy","volume":"15","author":"Cocco","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.lfs.2024.122614_bb0565","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.2217\/cer-2021-0247","article-title":"Comparative effectiveness of larotrectinib versus entrectinib for the treatment of metastatic NTRK gene fusion cancers","volume":"11","author":"Suh","year":"2022","journal-title":"Journal of Comparative Effectiveness Research"},{"key":"10.1016\/j.lfs.2024.122614_bb0570","first-page":"418","article-title":"Larotrectinib and Entrectinib: TRK inhibitors for the treatment of pediatric and adult patients with NTRK gene fusion","volume":"11","author":"Dunn","year":"2020","journal-title":"J. Adv. Pract. Oncol."},{"key":"10.1016\/j.lfs.2024.122614_bb0575","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.3390\/ijms23062916","article-title":"The challenge and opportunity of NTRK inhibitors in non-small cell lung Cancer","volume":"23","author":"Qin","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2024.122614_bb0580","doi-asserted-by":"crossref","first-page":"5430","DOI":"10.3390\/cancers14215430","article-title":"KRAS in NSCLC: state of the art and future perspectives","volume":"14","author":"Cascetta","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.lfs.2024.122614_bb0585","article-title":"KRAS-mutant non-small cell lung cancer: an emerging promisingly treatable subgroup","volume":"11","author":"Xie","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.lfs.2024.122614_bb0590","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jtho.2018.12.013","article-title":"K-ras mutation subtypes in NSCLC and associated co-occuring mutations in other oncogenic pathways","volume":"14","author":"Scheffler","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lfs.2024.122614_bb0595","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.796832","article-title":"Targeting KRAS mutant in non-small cell lung cancer: novel insights into therapeutic strategies","volume":"12","author":"D\u00e9sage","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.lfs.2024.122614_bb0600","doi-asserted-by":"crossref","DOI":"10.21037\/tlcr-20-927","article-title":"Prognostic and predictive effect of KRAS gene copy number and mutation status in early stage non-small cell lung cancer patients","volume":"10","author":"Fung","year":"2021","journal-title":"Translational Lung Cancer Research"},{"key":"10.1016\/j.lfs.2024.122614_bb0605","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.3390\/jpm12101651","article-title":"Deciphering the impact of HER2 alterations on non-small-cell lung cancer: from biological mechanisms to therapeutic approaches","volume":"12","author":"Bontoux","year":"2022","journal-title":"Journal of Personalized Medicine"},{"key":"10.1016\/j.lfs.2024.122614_bb0610","unstructured":"Ying Yu, Yehao Yang. Targeting HER2 alterations in non-small cell lung cancer: therapeutic breakthrough and challenges - Cancer Treat. Rev. n.d. https:\/\/www.cancertreatment-reviews.com\/article\/S0305-7372(23)00011-7\/fulltext (accessed November 3, 2023)."},{"key":"10.1016\/j.lfs.2024.122614_bb0615","article-title":"Drug-resistant HER2-positive breast cancer: molecular mechanisms and overcoming strategies","volume":"13","author":"Wu","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.lfs.2024.122614_bb0620","article-title":"TP53 co-mutations in advanced EGFR-mutated non\u2013small cell lung cancer: prognosis and therapeutic strategy for cancer therapy","volume":"12","author":"Liu","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.lfs.2024.122614_bb0625","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41573-022-00571-8","article-title":"Drugging p53 in cancer: one protein, many targets","volume":"22","author":"Hassin","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.lfs.2024.122614_bb0630","doi-asserted-by":"crossref","first-page":"429","DOI":"10.3390\/cancers15020429","article-title":"Drugs targeting p53 mutations with FDA approval and in clinical trials","volume":"15","author":"Nishikawa","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.lfs.2024.122614_bb0635","unstructured":"Concurrent TP53 mutations predict a poor prognosis of EGFR-mutant NSCLCs treated with TKIs: an updated systematic review and meta-analysis n.d. https:\/\/www.spandidos-publications.com\/10.3892\/ol.2022.13504 (accessed March 27, 2024)."},{"key":"10.1016\/j.lfs.2024.122614_bb0640","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.3390\/nano12162826","article-title":"Recent advances in functionalized nanoparticles in cancer theranostics","volume":"12","author":"Siddique","year":"2022","journal-title":"Nanomaterials"},{"key":"10.1016\/j.lfs.2024.122614_bb0645","first-page":"140","article-title":"Current role of nanoparticles in the treatment of lung cancer","volume":"7","author":"Carrasco-Esteban","year":"2021","journal-title":"J Clin Transl Res"},{"key":"10.1016\/j.lfs.2024.122614_bb0650","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1007\/s13346-021-01088-0","article-title":"Pulmonary delivery of osimertinib liposomes for non-small cell lung cancer treatment: formulation development and in vitro evaluation","volume":"12","author":"Sawant","year":"2022","journal-title":"Drug Deliv and Transl Res"},{"key":"10.1016\/j.lfs.2024.122614_bb0655","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jconrel.2021.02.031","article-title":"Polymeric micelles in drug delivery: an insight of the techniques for their characterization and assessment in biorelevant conditions","volume":"332","author":"Ghezzi","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.lfs.2024.122614_bb0660","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2020.587997","article-title":"Solid lipid nanoparticles for drug delivery: pharmacological and biopharmaceutical aspects","volume":"7","author":"Scioli Montoto","year":"2020","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.lfs.2024.122614_bb0665","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s11671-021-03632-w","article-title":"Multifunctional gold nanoparticles for improved diagnostic and therapeutic applications: a review","volume":"16","author":"Sibuyi","year":"2021","journal-title":"Nano- scale Res Lett"},{"key":"10.1016\/j.lfs.2024.122614_bb0670","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.ijbiomac.2022.09.250","article-title":"Human serum albumin-poly(Lactide)-conjugated self-assembly NPs for targeted docetaxel delivery and improved therapeutic efficacy in oral cancer","volume":"222","author":"Kumbham","year":"2022","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.lfs.2024.122614_bb0675","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/1061186X.2019.1648479","article-title":"Liposome\u2013ligand conjugates: a review on the current state of art","volume":"28","author":"Ero\u011flu","year":"2020","journal-title":"J. Drug Target."},{"key":"10.1016\/j.lfs.2024.122614_bb0680","series-title":"Albumin in Medicine: Pathological and Clinical Applications","first-page":"101","article-title":"Nanoparticle albumin-bound paclitaxel (Abraxane\u00ae)","author":"Desai","year":"2016"},{"key":"10.1016\/j.lfs.2024.122614_bb0685","doi-asserted-by":"crossref","first-page":"S1083","DOI":"10.1016\/j.jtho.2016.11.1513","article-title":"P2.06-020 a open-label randomised controlled trial of first-line genexol-PM\/CrEL-based paclitaxel plus cisplatin in advanced NSCLC patients: topic: phase II + NK","volume":"12","author":"Han","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lfs.2024.122614_bb0690","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1154318","article-title":"The use of nanoparticles for targeted drug delivery in non-small cell lung cancer","volume":"13","author":"Holder","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.lfs.2024.122614_bb0695","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.2147\/IJN.S290263","article-title":"Synergistic antitumor efficacy mediated by liposomal co-delivery of polymeric micelles of vinorelbine and cisplatin in non-small cell lung cancer","volume":"16","author":"Wang","year":"2021","journal-title":"IJN"},{"key":"10.1016\/j.lfs.2024.122614_bb0700","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12645-023-00199-2","article-title":"Non-small cell lung cancer targeted nanoparticles with reduced side effects fabricated by flash nanoprecipitation","volume":"14","author":"Wang","year":"2023","journal-title":"Cancer Nano- technology"},{"key":"10.1016\/j.lfs.2024.122614_bb0705","doi-asserted-by":"crossref","first-page":"4692","DOI":"10.1021\/acs.nanolett.9b01774","article-title":"Precision nanomedicine development based on specific opsonization of human cancer patient-personalized protein coronas","volume":"19","author":"Ren","year":"2019","journal-title":"Nano Lett."},{"key":"10.1016\/j.lfs.2024.122614_bb0710","doi-asserted-by":"crossref","first-page":"466","DOI":"10.3390\/jfb14090466","article-title":"Targeted EGFR nanotherapy in non-small cell lung cancer","volume":"14","author":"Crintea","year":"2023","journal-title":"Journal of Functional Biomaterials"},{"key":"10.1016\/j.lfs.2024.122614_bb0715","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.actbio.2021.05.018","article-title":"Nanoparticles for co-delivery of osimertinib and selumetinib to overcome osimertinib-acquired resistance in non-small cell lung cancer","volume":"129","author":"Chen","year":"2021","journal-title":"Acta Biomater."},{"key":"10.1016\/j.lfs.2024.122614_bb0720","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202201516","article-title":"Targeted drug\/gene\/photodynamic therapy via a stimuli-responsive dendritic-polymer-based nanococktail for treatment of EGFR-TKI-resistant non-small-cell lung cancer","volume":"34","author":"Huang","year":"2022","journal-title":"Adv. Mater."},{"key":"10.1016\/j.lfs.2024.122614_bb0725","article-title":"Targeted co-delivery of gefitinib and rapamycin by aptamer-modified nanoparticles overcomes EGFR-TKI resistance in NSCLC via promoting autophagy","volume":"23","author":"Liu","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2024.122614_bb0730","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.7150\/thno.24469","article-title":"Dual target gene therapy to EML4-ALK NSCLC by a gold nanoshell-based system","volume":"8","author":"Li","year":"2018","journal-title":"Theranostics"},{"key":"10.1016\/j.lfs.2024.122614_bb0735","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.omtn.2023.07.027","article-title":"Targeting oncogenic KRAS in non-small cell lung cancer with EGFR aptamer-conjugated multifunctional RNA nanoparticles","volume":"33","author":"Yang","year":"2023","journal-title":"Molecular Therapy - Nucleic Acids"},{"key":"10.1016\/j.lfs.2024.122614_bb0740","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s12943-022-01681-y","article-title":"Single low-dose INC280-loaded theranostic nanoparticles achieve multirooted delivery for MET-targeted primary and liver metastatic NSCLC","volume":"21","author":"Sun","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.lfs.2024.122614_bb0745","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jconrel.2023.09.044","article-title":"A redox-responsive nanosystem to suppress chemoresistant lung cancer through targeting STAT3","volume":"363","author":"Feng","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.lfs.2024.122614_bb0750","doi-asserted-by":"crossref","DOI":"10.1016\/j.cej.2020.126801","article-title":"Biomimetic carrier-free nanoparticle delivers digoxin and doxorubicin to exhibit synergetic antitumor activity in vitro and in vivo","volume":"406","author":"Zhang","year":"2021","journal-title":"Chem. Eng. J."},{"key":"10.1016\/j.lfs.2024.122614_bb0755","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1007\/s00210-023-02522-5","article-title":"Nano-mediated strategy for targeting and treatment of non-small cell lung cancer (NSCLC)","volume":"396","author":"Ashique","year":"2023","journal-title":"Naunyn Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"10.1016\/j.lfs.2024.122614_bb0760","doi-asserted-by":"crossref","DOI":"10.1016\/j.microc.2023.108893","article-title":"Multi-signal amplification electrochemilumine- scence biosensor based on GO-CDTPA-AuNPs composites and PET-RAFT for ultrasensitive detection of KRAS G12C mutation","volume":"191","author":"Sun","year":"2023","journal-title":"Microchem. J."},{"key":"10.1016\/j.lfs.2024.122614_bb0765","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2023.113517","article-title":"Detection of CYFRA 21-1 in human serum by an electrochemical immunosensor based on UiO-66-NH2@CMWCNTs and CS@AuNPs","volume":"230","author":"Cai","year":"2023","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.lfs.2024.122614_bb0770","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.actbio.2020.03.004","article-title":"Near-infrared\/pH dual-responsive nanocomplexes for targeted imaging and chemo\/gene\/photothermal tri-therapies of non-small cell lung cancer","volume":"107","author":"Li","year":"2020","journal-title":"Acta Biomater."},{"key":"10.1016\/j.lfs.2024.122614_bb0775","doi-asserted-by":"crossref","first-page":"4535","DOI":"10.1021\/acsbiomaterials.2c00620","article-title":"A self-assembly ICG nanoparticle potentiating targeted photothermal and photodynamic therapy in NSCLC","volume":"8","author":"Hu","year":"2022","journal-title":"ACS Biomater Sci. Eng."},{"key":"10.1016\/j.lfs.2024.122614_bb0780","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.3390\/pharmaceutics13071063","article-title":"Multifunctional lipid-based nanoparticles for codelivery of anticancer drugs and siRNA for treatment of non-small cell lung cancer with different level of resistance and EGFR mutations","volume":"13","author":"Majumder","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.lfs.2024.122614_bb0785","doi-asserted-by":"crossref","first-page":"673","DOI":"10.3390\/jpm12050673","article-title":"The promise of nano-technology in personalized medicine","volume":"12","author":"Alghamdi","year":"2022","journal-title":"J Pers Med"},{"key":"10.1016\/j.lfs.2024.122614_bb0790","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/s41578-020-00269-6","article-title":"Targeted drug delivery strategies for precision medicines","volume":"6","author":"Manzari","year":"2021","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.lfs.2024.122614_bb0795","author":"Li"},{"key":"10.1016\/j.lfs.2024.122614_bb0800","author":"Shu"},{"key":"10.1016\/j.lfs.2024.122614_bb0805","author":"Royal Marsden NHS Foundation Trust"},{"key":"10.1016\/j.lfs.2024.122614_bb0810","author":"Genprex, Inc"},{"key":"10.1016\/j.lfs.2024.122614_bb0815","author":"BIND Therapeutics"}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320524002042?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320524002042?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T18:09:59Z","timestamp":1726855799000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320524002042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":163,"alternative-id":["S0024320524002042"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2024.122614","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Precision nanomedicine to treat non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2024.122614","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"122614"}}